Literature DB >> 16451409

Pneumocystis jirovecii colonisation in patients with interstitial lung disease.

S Vidal1, C de la Horra, J Martín, M A Montes-Cano, E Rodríguez, N Respaldiza, F Rodríguez, J M Varela, F J Medrano, E J Calderón.   

Abstract

A prospective study was conducted to determine the prevalence of colonisation by Pneumocystis jirovecii in 80 consecutive patients who required bronchoscopy and bronchoalveolar lavage (BAL) following suspicion of interstitial lung disease (ILD). The mtLSU rRNA gene of P. jirovecii was identified by nested PCR in BAL samples. Patients with ILDs were divided into three groups: group A comprised those with idiopathic interstitial pneumonias; group B comprised those with sarcoidosis; and group C comprised those with other ILDs. The overall prevalence of P. jirovecii carriage was 33.8%, with colonisation rates of 37.8%, 18.8% and 37% in groups A, B and C, respectively (p not significant). There were more smokers among the carriers, but there were no other significant differences between carriers and non-carriers. The high prevalence of P. jirovecii carriers found among immunocompetent patients with ILDs in Spain suggests a possible role of P. jirovecii in the natural history of these diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16451409     DOI: 10.1111/j.1469-0691.2005.01337.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  31 in total

1.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

2.  Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial.

Authors:  Andrew M Wilson; Allan B Clark; Tony Cahn; Edwin R Chilvers; William Fraser; Matthew Hammond; David M Livermore; Toby M Maher; Helen Parfrey; Ann Marie Swart; Susan Stirling; David R Thickett; Moira Whyte
Journal:  JAMA       Date:  2020-12-08       Impact factor: 56.272

Review 3.  Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.

Authors:  James A Grubbs; John W Baddley
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

4.  Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay.

Authors:  Philippe M Hauser; Jacques Bille; Cornelia Lass-Flörl; Christian Geltner; Marta Feldmesser; Michael Levi; Hitesh Patel; Victoria Muggia; Barbara Alexander; Martin Hughes; Sarah A Follett; Xiaohui Cui; Flora Leung; Gillian Morgan; Adrian Moody; David S Perlin; David W Denning
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 5.  High-resolution CT of complications of idiopathic fibrotic lung disease.

Authors:  C R Lloyd; S L F Walsh; D M Hansell
Journal:  Br J Radiol       Date:  2011-07       Impact factor: 3.039

Review 6.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

Review 7.  [Chronic critically ill patients from a pneumological perspective].

Authors:  M Pfeifer
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-04-12       Impact factor: 0.840

8.  Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study.

Authors:  Yasuo Shimizu; Noriaki Sunaga; Kunio Dobashi; Makoto Fueki; Naoto Fueki; Sohei Makino; Masatomo Mori
Journal:  BMC Infect Dis       Date:  2009-04-22       Impact factor: 3.090

9.  Pneumocystis jirovecii transmission from immunocompetent carriers to infant.

Authors:  Laura Rivero; Carmen de la Horra; Marco A Montes-Cano; Alfonso Rodríguez-Herrera; Nieves Respaldiza; Vicente Friaza; Rubén Morilla; Sonia Gutiérrez; José M Varela; Francisco J Medrano; Enrique J Calderón
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

10.  Risk Factors of Mortality From Pneumocystis Pneumonia in Non-HIV Patients: A Meta-Analysis.

Authors:  Yuqiong Wang; Xiaoyi Zhou; Maidinuer Saimi; Xu Huang; Ting Sun; Guohui Fan; Qingyuan Zhan
Journal:  Front Public Health       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.